Flavivirus Infections is an indication for drug development with over 250 pipeline drugs currently active. According to GlobalData, preregistered drugs for Flavivirus Infections have a 75% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Flavivirus Infections compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Flavivirus Infections overview
Flavivirus infections are caused by a group of viruses that belong to the Flaviviridae family. These viruses are transmitted by mosquitoes or ticks and can affect humans and animals. Flavivirus infections can cause various diseases, such as yellow fever, dengue, Zika, West Nile, and Japanese encephalitis. The symptoms of these diseases may include fever, headache, rash, bleeding, shock, neurological complications, and birth defects. Flavivirus infections are diagnosed by laboratory tests that detect the virus or its antibodies in the blood or cerebrospinal fluid. There is no specific treatment for flavivirus infections, but supportive care and prevention measures can reduce the severity and spread of the diseases. Some flavivirus infections can be prevented by vaccines, such as yellow fever and Japanese encephalitis vaccines. Other flavivirus infections can be prevented by avoiding mosquito or tick bites, using insect repellents, wearing protective clothing, and eliminating mosquito breeding sites.
For a complete picture of PTSR and LoA scores for drugs in Flavivirus Infections, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
